March 21, 2017 / 8:15 AM / 9 months ago

BRIEF-Poxel announces results for QT safety clinical study of Imeglimin

March 21 (Reuters) - Poxel SA:

* Announces positive results for thorough QT safety clinical study of Imeglimin

* It has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Imeglimin in 55 healthy subjects

* Imeglimin showed no effect on QT/QTc interval at a dose of 2250 mg and at a higher dose of 6000 mg

* Study also showed that Imeglimin had a consistent pharmacokinetic profile at doses tested Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below